Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,133 public trials 2,035 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, not recruiting

Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance

NCT06070961

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +32 more
Locations
  • Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico Avellino, AV, Italy
  • A.O. SS. Antonio e Biagio e Cesare Arrigo, S.C. Ematologia Alessandria, IT, Italy
  • Nuovo Ospedale degli Infermi, SSD Ematologia Biella, IT, Italy
  • ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia Milan, IT, Italy
View all 14 locations
View Trial Details
Active, not recruiting

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

NCT02520791

Conditions
Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +29 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Smilow Cancer Center/Yale-New Haven Hospital New Haven, Connecticut, United States
  • Yale University New Haven, Connecticut, United States
View all 23 locations
View Trial Details
Active, not recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

NCT07150104

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Salvador, Estado de Bahia, Brazil
  • GSK Investigational Site Porto Alegre, Rio Grande do Sul, Brazil
  • GSK Investigational Site Halifax, Nova Scotia, Canada
  • GSK Investigational Site Villejuif, France
View Trial Details
Active, not recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

NCT07217184

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Grand Rapids, Michigan, United States
  • GSK Investigational Site Madison, Wisconsin, United States
View all 19 locations
View Trial Details
Active, not recruiting

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01562405

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Emory University Atlanta, Georgia, United States
  • Massachusetts General Hosptial Boston, Massachusetts, United States
  • Brigham and Women's Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Active, not recruiting

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

NCT06253663

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Chiba University Hospital Chiba, Japan
  • Kyushu University Hospital Fukuoka, Japan
  • Hokkaido University Hospital Hokkaido, Japan
  • Kyoto University Hospital Kyoto, Japan
View Trial Details
Active, not recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

NCT07217119

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Madison, Wisconsin, United States
  • GSK Investigational Site Fitzroy, Victoria, Australia
  • GSK Investigational Site Melbourne, Victoria, Australia
View Trial Details
Active, not recruiting

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

NCT04509700

Conditions
B-cell Malignancies, Bone Marrow Diseases, Hematologic Diseases, +10 more
Locations
  • Uab Comprehensive Cancer Center Birmingham, Alabama, United States
  • University of Alabama At Birmingham Birmingham, Alabama, United States
  • Mayo Clinic Rochester Phoenix, Arizona, United States
  • University of Arizona Cancer Center-Out Pt. Tucson, Arizona, United States
View all 105 locations
View Trial Details

Related conditions